- Home
- REI vs ACRS Comparison
REI vs ACRS Comparison
Compare REI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- ACRS
- Stock Information
- Founded
- REI 2004
- ACRS 2012
- Country
- REI United States
- ACRS United States
- Employees
- REI N/A
- ACRS N/A
- Industry
- REI Oil & Gas Production
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- REI Energy
- ACRS Health Care
- Exchange
- REI Nasdaq
- ACRS Nasdaq
- Market Cap
- REI 206.5M
- ACRS 230.8M
- IPO Year
- REI N/A
- ACRS 2015
- Fundamental
- Price
- REI $0.94
- ACRS $2.46
- Analyst Decision
- REI
- ACRS Strong Buy
- Analyst Count
- REI 0
- ACRS 9
- Target Price
- REI N/A
- ACRS $9.25
- AVG Volume (30 Days)
- REI 2.0M
- ACRS 1.4M
- Earning Date
- REI 11-06-2025
- ACRS 11-06-2025
- Dividend Yield
- REI N/A
- ACRS N/A
- EPS Growth
- REI N/A
- ACRS N/A
- EPS
- REI N/A
- ACRS N/A
- Revenue
- REI $308,790,652.00
- ACRS $15,742,000.00
- Revenue This Year
- REI N/A
- ACRS N/A
- Revenue Next Year
- REI $6.98
- ACRS N/A
- P/E Ratio
- REI N/A
- ACRS N/A
- Revenue Growth
- REI N/A
- ACRS N/A
- 52 Week Low
- REI $0.72
- ACRS $1.05
- 52 Week High
- REI $1.62
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- REI 44.50
- ACRS 57.34
- Support Level
- REI $0.92
- ACRS $2.38
- Resistance Level
- REI $0.99
- ACRS $2.61
- Average True Range (ATR)
- REI 0.05
- ACRS 0.24
- MACD
- REI -0.00
- ACRS 0.00
- Stochastic Oscillator
- REI 23.10
- ACRS 60.83
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.